The Role of Salivary Biomarkers in Early Detection of Oral Precancerous Lesions

Abstract

Background: Oral precancerous lesions are potentially malignant disorders that carry a high risk of transformation into oral cancer if not detected early. Conventional diagnostic methods rely on invasive biopsies, highlighting the need for reliable, non-invasive biomarkers. Salivary malondialdehyde (MDA), interleukin-6 (IL-6), and lactate dehydrogenase (LDH) reflect oxidative stress, inflammation, and tissue injury, respectively, and may serve as valuable diagnostic tools.  Objectives: To measure and compare salivary levels of MDA, IL-6, and LDH between patients with oral precancerous lesions and individuals without such lesions, and to assess their diagnostic potential. Methods: A case-control study was conducted at the Oncology Center, Medical City, Baghdad, Iraq, between August 2024 and March 2025. A total of 102 participants were enrolled: 54 patients with clinically and histopathologically confirmed oral precancerous lesions and 48 lesion-free controls. Unstimulated saliva samples were collected under standardized conditions and analyzed for MDA, IL-6, and LDH levels using validated biochemical methods. Statistical analyses, including ROC curve evaluation, were performed to assess diagnostic accuracy. Results: Patients with oral precancerous lesions exhibited significantly higher salivary concentrations of MDA, IL-6, and LDH compared to negative cases (p < 0.05). ROC analysis demonstrated good diagnostic performance for all three biomarkers, with IL-6 showing the highest area under the curve, followed by MDA and LDH. No significant gender-based differences were observed in biomarker expression. Conclusion: Elevated salivary levels of MDA, IL-6, and LDH are strongly associated with oral precancerous lesions, suggesting their utility as non-invasive biomarkers for early detection. Incorporating these salivary assays into routine screening may facilitate timely intervention and reduce the progression to oral cancer.

Keywords:

Interleukin-6, MDA, LDH, saliva, ROC

References

Al-Fahham, A.A. (2018) Development of New LSD Formula when Unequal Observations Numbers of Observations Are. Open Journal of Statistics, , 8, 258-263.https://doi.org/10.4236/ojs.2018.82016.

Ayala, A., Muñoz, M. F., & Argüelles, S. (2014). Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cellular Longevity, 2014, 360438.

Baba, S., Ikeda, T., & Sakaguchi, H. (2016). Salivary interleukin-6 levels in oral potentially malignant disorders and oral squamous cell carcinoma. Oral Diseases, 22(5), 443–449.

Baharvand, M., Manifar, S., Akkafan, R., Mortazavi, H., & Sabour, S. (2014). Serum levels of malondialdehyde as a biomarker of oral squamous cell carcinoma. Asian Pacific Journal of Cancer Prevention, 15(2), 747–750.

Bharath, T. S., Raghunath, V., Reddy, B. V., & Naik, R. (2020). Salivary lactate dehydrogenase as a biomarker in oral precancer and cancer: A systematic review. Journal of Oral and Maxillofacial Pathology, 24(2), 237–243.

Bonne, N. J., & Wong, D. T. W. (2012). Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Medicine, 4(10), 82.

Deepthi, G., & Nandan, S. R. K. (2020). Salivary biomarkers in oral potentially malignant disorders: A systematic review. Journal of Oral and Maxillofacial Pathology, 24(1), 148–153.

Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2010). Tumor markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. European Journal of Cancer, 46(3), 511–523.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.

Gupta, S., Sharma, A., & Bansal, R. (2019). Oxidative stress in oral precancerous lesions and oral cancer. Journal of Oral Biology and Craniofacial Research, 9(3), 236–241.

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nature Reviews Clinical Oncology, 15(4), 234–248.

Kaczor-Urbanowicz, K. E., Wei, F., Rao, S. L., Kim, J., Shin, H., Cheng, J., & Wong, D. T. (2017). Clinical validity of saliva and novel technology for cancer detection. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1868(1), 231–243.

Kaur, J., Jacobs, R., Huang, Y., Salvo, N., Politis, C., & Shahdad, S. (2016). Salivary biomarkers for oral cancer and pre-cancer screening: Systematic review. British Dental Journal, 221(10), 557–566.

Kaur, S., Prasad, S., & Singh, A. (2017). Lactate dehydrogenase as a biomarker in oral premalignancy and malignancy: A biochemical study. Journal of Cancer Research and Therapeutics, 13(4), 701–705.

Lee, Y. H., Wong, D. T. (2020). Saliva: An emerging biofluid for early detection of diseases. American Journal of Dentistry, 33(2), 74–81.

Malik, R., Singh, P., & Kumar, A. (2020). Salivary diagnostics in oral cancer: Opportunities and challenges. Oral Oncology, 102, 104540.

Miller, J., Dostalek, M., & Chen, W. (2019). Gender differences in inflammatory and oxidative stress biomarkers: Implications for disease susceptibility. Biology of Sex Differences, 10(1), 20.

Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Biology and Medicine, 49(11), 1603–1616.

Sculley, D. V., & Langley-Evans, S. C. (2003). Salivary antioxidants and markers of oxidative stress in dental caries and periodontal disease. International Journal of Dental Hygiene, 1(4), 188–194.

Speight, P. M., & Khurram, S. A. (2018). Oral potentially malignant disorders: Risk of progression to malignancy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 125(6), 612–627.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

Warnakulasuriya, S., Kujan, O., Aguirre-Urizar, J. M., Bagan, J. V., González-Moles, M. Á., Kerr, A. R., Lodi, G., Mello, F. W., Monteiro, L., Ogden, G. R., Sloan, P., & Johnson, N. W. (2020). Oral potentially malignant disorders: A consensus report from an international seminar. Oral Diseases, 27(8), 1862–1880.

Yakob, M., Fuentes, L., Wang, M. B., Abemayor, E., & Wong, D. T. W. (2014). Salivary biomarkers for detection of oral squamous cell carcinoma – current state and recent advances. Current Oral Health Reports, 1(2), 133–141.

Zhang, L., Xiao, H., & Wong, D. T. (2018). Salivary biomarkers for clinical applications. Molecular Diagnosis & Therapy, 22(5), 479–490.

Zhou, X., Li, X., & Li, Y. (2019). Factors affecting salivary biomarker levels: Considerations for research and clinical practice. Journal of Oral Pathology & Medicine, 48(5), 381–389.